Cancer Breakthrough Sends Telomir Pharma Stock Exploding 157% - Wall Street Pit

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 tumor models.

Cancer Breakthrough Sends Telomir Pharma Stock Exploding 157% - Wall Street Pit

Telomir Pharmaceuticals Inc. (TELO) stock surged 157% to $3.11 in premarket trading after reporting that Telomir-1 fully reversed epigenetic silencing of the STAT1 tumor suppressor gene in aggressive prostate cancer cells, outperforming Paclitaxel and Rapamycin. Telomir-1 also reduced hypermethylation of the TMS1 gene, offering a dual mechanism to enhance immune…